New Study in Journal of Hepatology: Can Breastfeeding Your Baby Lower Your Risk of Nonalcoholic Fatty Liver Disease Later in Life?
Source: Pixabay.com

New Study in Journal of Hepatology: Can Breastfeeding Your Baby Lower Your Risk of Nonalcoholic Fatty Liver Disease Later in Life?

  A new published research study shows that women who breastfeed at least one child for six months or more are at a lower risk of having nonalcoholic fatty liver…

Continue Reading New Study in Journal of Hepatology: Can Breastfeeding Your Baby Lower Your Risk of Nonalcoholic Fatty Liver Disease Later in Life?

ICYMI: Potential Treatment in the Works for Familial Amyotrophic Lateral Sclerosis

According to a story from telegram.com, a group of researchers from the University of Massachusetts medical school recently announced that they may have reached a major treatment breakthrough for genetically…

Continue Reading ICYMI: Potential Treatment in the Works for Familial Amyotrophic Lateral Sclerosis
Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
allinonemovie / Pixabay

Rare Blood Cancer Trial Data to be Presented in Upcoming Conference

According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…

Continue Reading Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
Bioverativ Presents Updates on Treatments and Research for Sickle Cell Anemia and Hemophilia
Cozendo / Pixabay

Bioverativ Presents Updates on Treatments and Research for Sickle Cell Anemia and Hemophilia

According to a story from Business Wire, the drug developer Bioverativ, Inc., recently announced its intention to present data related to its latest developments in blood disorder therapies. This data…

Continue Reading Bioverativ Presents Updates on Treatments and Research for Sickle Cell Anemia and Hemophilia

New Collaborative Clinical Trial Announced to Test Experimental Urothelial Cancer Treatment

According to a story from PRNewswire, Infinity Pharmaceuticals and the Bristol-Myers Squibb Company recently announced that the two companies will be partnering in order to conduct a Phase 2 clinical…

Continue Reading New Collaborative Clinical Trial Announced to Test Experimental Urothelial Cancer Treatment
Researchers were Wrong about the Cause of Muscular Dystrophy
qimono / Pixabay

Researchers were Wrong about the Cause of Muscular Dystrophy

For a long time, neuromuscular diseases such as muscular dystrophy, ALS, and inclusion body myopathy were thought to be caused as a result of toxic clumps of proteins such as TDP-43.…

Continue Reading Researchers were Wrong about the Cause of Muscular Dystrophy
New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1
jniittymaa0 / Pixabay

New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1

Alnylam has provided updates about their programs for patients with primary hyperoxaluria type 1 (PH1), a rare condition that affects the kidneys and bladder. As part of their Alnylam Act® program,…

Continue Reading New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1

Start-Up Develops AI Tech to Find Treatments for Rare Diseases; Wants to Help 100 Diseases by 2025

Forbes reports that Healx, a British biotech startup, is using the power of artificial intelligence to find new uses for existing drugs that treat rare diseases. "Healx combines AI technology, pharmacology…

Continue Reading Start-Up Develops AI Tech to Find Treatments for Rare Diseases; Wants to Help 100 Diseases by 2025
Licensing Agreement Struck for an Experimental Sanfilippo Syndrome Drug
rawpixel / Pixabay

Licensing Agreement Struck for an Experimental Sanfilippo Syndrome Drug

According to a story from publicnow.com, the drug development company Sarepta Therapeutics recently announced that is has completed negotiations for a licensing agreement with Lysogene, a biopharmaceutical company. This agreement…

Continue Reading Licensing Agreement Struck for an Experimental Sanfilippo Syndrome Drug